Vivesto (OMX: VIVE)

Last close As at 18/04/2024

0.42

−0.02 (−4.55%)

Market capitalisation

228m

Latest Insights

View More

Healthcare | Update

Vivesto — Turnaround strategy beginning to deliver

Healthcare | Flash note

Oasmia Pharmaceutical — Delivering on promises

Healthcare | edison tv

Oasmia Pharmaceutical: Edison Open House Healthcare 2022

Healthcare | edison tv

Oasmia Pharmaceutical – executive interview

Sector

Healthcare

Balance Sheet

Forecast net debt (SEKm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (9.8) (40.8) (83.9)
Relative (9.2) (46.3) (79.2)
52 week high/low SEK2.7/SEK0.3

Financials

Edison Investment Research is terminating coverage on Vivesto (VIVE), Diurnal Group (DNL), Palace Capital (PCA), Primary Health Properties (PHP), Silver One Resources (SVE), Induction Healthcare (INHC) and Axiom European Financial Debt (AXI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2020A 0.5 (102.6) (140.3) (24.8) N/A N/A
2021A 26.2 (99.8) (132.7) (24.6) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Research

edison tv

Healthcare

Oasmia Pharmaceutical – executive interview

Update

Healthcare

Oasmia Pharmaceutical — A definitive year ahead

Outlook

Healthcare

Oasmia Pharmaceutical — Focused on pillars of growth

Update

Healthcare

Oasmia Pharmaceutical — Onwards and upwards

edison tv

Healthcare

Oasmia Pharmaceutical – executive interview

Initiation

Healthcare

Oasmia Pharmaceutical — An appealing metamorphosis

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free